Free Trial

Cidara Therapeutics (CDTX) Competitors

$11.82
+0.05 (+0.42%)
(As of 05/29/2024 ET)

CDTX vs. DYAI, ALGS, INAB, OKYO, GNTA, NKGN, CYTH, ACHL, QNCX, and TARA

Should you be buying Cidara Therapeutics stock or one of its competitors? The main competitors of Cidara Therapeutics include Dyadic International (DYAI), Aligos Therapeutics (ALGS), IN8bio (INAB), OKYO Pharma (OKYO), Genenta Science (GNTA), NKGen Biotech (NKGN), Cyclo Therapeutics (CYTH), Achilles Therapeutics (ACHL), Quince Therapeutics (QNCX), and Protara Therapeutics (TARA). These companies are all part of the "biological products, except diagnostic" industry.

Cidara Therapeutics vs.

Dyadic International (NASDAQ:DYAI) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, community ranking, profitability, analyst recommendations, earnings and dividends.

28.0% of Dyadic International shares are held by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are held by institutional investors. 28.8% of Dyadic International shares are held by company insiders. Comparatively, 7.4% of Cidara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Dyadic International currently has a consensus target price of $6.00, indicating a potential upside of 195.57%. Cidara Therapeutics has a consensus target price of $71.25, indicating a potential upside of 501.27%. Given Dyadic International's stronger consensus rating and higher probable upside, analysts clearly believe Cidara Therapeutics is more favorable than Dyadic International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dyadic International
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Cidara Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25

Dyadic International has higher earnings, but lower revenue than Cidara Therapeutics. Dyadic International is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dyadic International$2.90M20.27-$6.80M-$0.28-7.18
Cidara Therapeutics$63.90M0.84-$22.93M-$7.68-1.53

Dyadic International has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500.

Cidara Therapeutics received 281 more outperform votes than Dyadic International when rated by MarketBeat users. Likewise, 70.24% of users gave Cidara Therapeutics an outperform vote while only 63.97% of users gave Dyadic International an outperform vote.

CompanyUnderperformOutperform
Dyadic InternationalOutperform Votes
158
63.97%
Underperform Votes
89
36.03%
Cidara TherapeuticsOutperform Votes
439
70.24%
Underperform Votes
186
29.76%

Cidara Therapeutics has a net margin of -73.46% compared to Cidara Therapeutics' net margin of -347.92%. Cidara Therapeutics' return on equity of -116.14% beat Dyadic International's return on equity.

Company Net Margins Return on Equity Return on Assets
Dyadic International-347.92% -116.14% -76.15%
Cidara Therapeutics -73.46%-201.62%-54.25%

In the previous week, Dyadic International and Dyadic International both had 4 articles in the media. Dyadic International's average media sentiment score of 1.59 beat Cidara Therapeutics' score of 1.32 indicating that Cidara Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dyadic International
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cidara Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Summary

Cidara Therapeutics beats Dyadic International on 13 of the 18 factors compared between the two stocks.

Get Cidara Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CDTX vs. The Competition

MetricCidara TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$53.72M$2.81B$4.96B$8.05B
Dividend YieldN/A2.85%2.80%3.97%
P/E Ratio-1.5313.21139.1615.77
Price / Sales0.84309.872,450.0972.66
Price / CashN/A168.7934.6931.30
Price / Book-3.026.845.474.57
Net Income-$22.93M-$47.92M$104.51M$213.29M
7 Day Performance-4.54%-5.15%-0.92%-1.13%
1 Month Performance-4.42%1.09%2.20%2.17%
1 Year Performance-56.69%1.53%4.92%6.99%

Cidara Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DYAI
Dyadic International
2.4791 of 5 stars
$1.67
+3.7%
$6.00
+259.4%
-10.5%$48.81M$2.90M-5.967Short Interest ↓
Positive News
Gap Up
High Trading Volume
ALGS
Aligos Therapeutics
2.2678 of 5 stars
$0.64
-4.5%
N/A-45.3%$49.87M$15.53M-0.5066Short Interest ↑
INAB
IN8bio
2.8778 of 5 stars
$1.01
-1.0%
$10.00
+890.1%
-62.6%$44.57MN/A-1.1131Short Interest ↓
OKYO
OKYO Pharma
3.1634 of 5 stars
$1.47
-1.3%
$7.00
+376.2%
-4.4%$42.96MN/A0.008Short Interest ↓
Positive News
Gap Down
GNTA
Genenta Science
2.759 of 5 stars
$3.03
-0.3%
$25.00
+725.7%
-43.5%$55.16MN/A0.0014Short Interest ↓
News Coverage
NKGN
NKGen Biotech
0 of 5 stars
$1.76
+2.9%
N/AN/A$39.60M$80,000.000.00N/AGap Down
CYTH
Cyclo Therapeutics
3.6109 of 5 stars
$1.36
-4.2%
$3.20
+135.3%
-0.6%$38.92M$1.13M-1.368Short Interest ↓
Positive News
Gap Down
ACHL
Achilles Therapeutics
2.4188 of 5 stars
$0.94
+1.1%
$4.00
+323.8%
-9.1%$38.78MN/A-0.59204Short Interest ↓
Positive News
Gap Down
QNCX
Quince Therapeutics
0 of 5 stars
$0.86
-4.4%
N/A-42.5%$37.17MN/A-1.1332Positive News
High Trading Volume
TARA
Protara Therapeutics
1.511 of 5 stars
$2.93
-2.0%
$26.50
+804.4%
-5.4%$60.33MN/A-0.7826Short Interest ↑
High Trading Volume

Related Companies and Tools

This page (NASDAQ:CDTX) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners